This thesis explored three new strategies for the delivery of poorly water-soluble drugs to the eye. Cyclosporine A and latanoprost are two drugs currently used in clinics for the treatment of highly prevalent ocular conditions (e.g. dry eye, ocular inflammation or glaucoma). These two drugs were selected as models since they are "practically insoluble" and their topical ophthalmic formulations need to be improved in regards to their stability, safety or availability. The three new strategies were based on: i) the use of a cyclosporine A prodrug, ii) the complexation of latanoprost with cyclodextrins and iii) the intraocular implantation of cyclosporine A loaded drug delivery systems. These three new formulations were demonstrated to be successful in overcoming the challenges with ocular delivery of poorly water-soluble drugs while improving drug stability, safety and availability. These new formulations represent promising options for the successful treatment of ocular conditions with minimal side effects.